Esquivel Carlos O, Marino Ignazio R, Iwatsuki Shunzaburo, Gordon Robert D, Van Thiel David, Starzl Thomas E
Departments of Surgery and Medicine, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15213.
Transplant Clin Immunol. 1987;19:185-196.
We have reviewed the long term results of the first 500 liver transplant recipients performed by our group during the cyclosporine era. Three hundred and forty-nine recipients lived (69.8%) more than 1 year and the projected 5 year actuarial survival for this sub-group of patients is 88%. The two most common causes of graft dysfunction after the first year were recurrence of the original disease, usually malignancy, and chronic rejection. Most episodes of rejection can be controlled with medical treatment; however, 16 patients of 34 patients who experienced rejection episodes after the first year required retransplantation. Eleven of these 16 are currently alive and free of jaundice. Another common cause of late graft dysfunction is biliary strictures. The recognized side effects of cyclosporine such as nephrotoxicity and lymphoproliferative disease have been lesser problems as a result of the judicious use of the drug. The quality of life of long term survivors is excellent.
我们回顾了在环孢素时代由我们团队进行的首批500例肝移植受者的长期结果。349名受者存活(69.8%)超过1年,该亚组患者预计的5年精算生存率为88%。术后第一年之后移植肝功能障碍的两个最常见原因是原发病复发,通常是恶性肿瘤,以及慢性排斥反应。大多数排斥反应发作可用药物治疗控制;然而,第一年之后经历排斥反应发作的34例患者中有16例需要再次移植。这16例患者中有11例目前存活且无黄疸。晚期移植肝功能障碍的另一个常见原因是胆管狭窄。由于谨慎使用环孢素,其公认的副作用如肾毒性和淋巴增殖性疾病已成为较小的问题。长期存活者的生活质量极佳。